Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist’s point of view

키워드

참고문헌 (87)

1. Solomon JJ, "Connective tissue disease-associated interstitial lung disease: a focused review", J Intensive Care Med, 30, pp.392~400 (2015)
2. Cottin V., "Idiopathic interstitial pneumonias with connective tissue diseases features: a review", Respirology, 21, pp.245~258 (2016)
3. Antoniou KM, "Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement", Eur Respir J, 33, pp.882~896 (2009)
4. Kowal-Bielecka O, "EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)", Ann Rheum Dis, 68, pp.620~628 (2009)
5. Saketkoo LA, "Interstitial lung disease in idiopathic inflammatory myopathy", Curr Rheumatol Rev, 6, pp.108~119 (2010)
6. Assayag D, "Determining respiratory impairment in connective tissue disease-associated interstitial lung disease", Rheum Dis Clin North Am, 41, pp.213~223 (2015)
7. Mathai SC, "Management of interstitial lung disease associated with connective tissue disease", BMJ, 352, pp.h6819~ (2016)
8. Ferri C, "Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: our interdisciplinary rheumatology-pneumology experience, and review of the literature", Autoimmun Rev, 15, pp.61~70 (2016)
9. Ryerson CJ, "Update on the diagnosis and classification of ILD", Curr Opin Pulm Med, 19, pp.453~459 (2013)
10. 김기조, "Applications of systems approaches in the study of rheumatic diseases", The Korean Journal of Internal Medicine, 30(2), pp.148~160 (2015), 대한내과학회[DOI]
11. Pereira DA, "Lung-dominant connective tissue disease among patients with interstitial lung disease: prevalence, functional stability, and common extrathoracic features", J Bras Pneumol, 41, pp.151~160 (2015)
12. Fischer A, "Interstitial lung disease evaluation:detecting connective tissue disease", Respiration, 90, pp.177~184 (2015)
13. Kornum JB, "The incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based study", BMC Pulm Med, 8, pp.24~ (2008)
14. Gabriel SE, "Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years", Arthritis Rheum, 48, pp.54~58 (2003)
15. Sung YK, "Prevalence and incidence of rheumatoid arthritis in South Korea", Rheumatol Int, 33, pp.1525~1532 (2013)
16. Arnett FC, "Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts", Arthritis Rheum, 44, pp.1359~1362 (2001)
17. Drosos AA, "Prevalence of primary Sjogren’s syndrome in an elderly population", Br J Rheumatol, 27, pp.123~127 (1988)
18. Gaubitz M., "Epidemiology of connective tissue disorders", Rheumatology (Oxford), 45(Suppl 3), pp.iii3~iii4 (2006)
19. Ju JH, "Prevalence of systemic lupus erythematosus in South Korea: an administrative database study", J Epidemiol, 24, pp.295~303 (2014)
20. Gunnarsson R, "The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients", Ann Rheum Dis, 70, pp.1047~1051 (2011)
21. Wallace B, "Management of connective tissue diseases associated interstitial lung disease:a review of the published literature", Curr Opin Rheumatol, 28, pp.236~245 (2016)
22. Bongartz T, "Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study", Arthritis Rheum, 62, pp.1583~1591 (2010)
23. Palm O, "Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality: a retrospective study based on registry data", Rheumatology (Oxford), 52, pp.173~179 (2013)
24. Yazisiz V, "Lung involvement in patients with primary Sjogren’s syndrome: what are the predictors?", Rheumatol Int, 30, pp.1317~1324 (2010)
25. Gunnarsson R, "Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study", Ann Rheum Dis, 71, pp.1966~1972 (2012)
26. Kiely PD, "Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis", Curr Rheumatol Rep, 15, pp.359~ (2013)
27. Selva-O’Callaghan A, "Polymyositis", dermatomyositis-associated lung disease:analysis of a series of 81 patients, 2005, pp.14, 534~542
28. Fathi M, "Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology", Arthritis Rheum, 59, pp.677~685 (2008)
29. Fidler L, "Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus", Lupus, 25, pp.1004~1011 (2016)
30. Doyle TJ, "Subclinical interstitial lung disease: why you should care", Am J Respir Crit Care Med, 185, pp.1147~1153 (2012)
31. Dawson JK, "Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests", Thorax, 56, pp.622~627 (2001)
32. Ortega-Hernandez OD, "Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment", Best Pract Res Clin Rheumatol, 26, pp.61~72 (2012)
33. Uffmann M, "Lung manifestation in asymptomatic patients with primary Sjogren syndrome: assessment with high resolution CT and pulmonary function tests", J Thorac Imaging, 16, pp.282~289 (2001)
34. Tashkin DP, "Cyclophosphamide versus placebo in scleroderma lung disease", N Engl J Med, 354, pp.2655~2666 (2006)
35. Nadashkevich O, "A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis", Clin Rheumatol, 25, pp.205~212 (2006)
36. Clements PJ, "The scleroderma lung study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofitil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSc)", Arthritis Rheumatol, 67(Suppl 10), pp.abstr1075~ (2015)
37. Daoussis D, "Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study", Rheumatology (Oxford), 49, pp.271~280 (2010)
38. Hoyles RK, "A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma", Arthritis Rheum, 54, pp.3962~3970 (2006)
39. Yoshiya Tanaka, "Current concepts in the management of rheumatoid arthritis", The Korean Journal of Internal Medicine, 31(2), pp.210~218 (2016), 대한내과학회[DOI]
40. Singh JA, "2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Rheumatol, 68, pp.1~26 (2016)
41. Assayag D, "Rheumatoid arthritis associated interstitial lung disease: a review", Medicina (B Aires), 74, pp.158~165 (2014)
42. Marigliano B, "Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis", Autoimmun Rev, 12, pp.1076~1084 (2013)
43. Emery P, "The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment:results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial", Arthritis Rheum, 54, pp.1390~1400 (2006)
44. Matteson EL, "Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia", Open J Rheumatol Autoimmune Dis, 2, pp.53~58 (2012)
45. Saketkoo LA, "Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects", Am J Med Sci, 337, pp.329~335 (2009)
46. Fischer A, "Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease", J Rheumatol, 40, pp.640~646 (2013)
47. Reina D, "Sjogren’s syndrome-associated interstitial lung disease: a multicenter study", Reumatol Clin, 12, pp.201~205 (2016)
48. Parambil JG, "Interstitial lung disease in primary Sjogren syndrome", Chest, 130, pp.1489~1495 (2006)
49. Ito I, "Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study", Am J Respir Crit Care Med, 171, pp.632~638 (2005)
50. Deheinzelin D, "Interstitial lung disease in primary Sjogren’s syndrome: clinical-pathological evaluation and response to treatment", Am J Respir Crit Care Med, 154(3 Pt 1), pp.794~799 (1996)
51. Devauchelle-Pensec V, "Treatment of primary Sjogren syndrome with rituximab:a randomized trial", Ann Intern Med, 160, pp.233~242 (2014)
52. Gottenberg JE, "Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry", Ann Rheum Dis, 72, pp.1026~1031 (2013)
53. Seror R, "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome", Ann Rheum Dis, 66, pp.351~357 (2007)
54. Lundberg IE., "The prognosis of mixed connective tissue disease", Rheum Dis Clin North Am, 31, pp.535~547 (2005)
55. Burdt MA, "Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings", Arthritis Rheum, 42, pp.899~909 (1999)
56. Yamasaki Y, "Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis", dermatomyositis, 2007, pp.46, 124~130
57. Mira-Avendano IC, "A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis", dermatomyositis, 2013, pp.107, 890~896
58. Ge Y, "Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review", Clin Rheumatol, 34, pp.99~105 (2015)
59. Ingegnoli F, "Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature", Autoimmun Rev, 11, pp.335~340 (2012)
60. Kameda H, "Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute", subacute interstitial pneumonia in patients with dermatomyositis, 2005, pp.32, 1719~1726
61. Lee CS, "Idiopathic inflammatory myopathy with diffuse alveolar damage", Clin Rheumatol, 21, pp.391~396 (2002)
62. Bertsias G, "EULAR recommendations for the management of systemic lupus erythematosus:report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics", Ann Rheum Dis, 67, pp.195~205 (2008)
63. Matthay RA, "Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis", Medicine (Baltimore), 54, pp.397~409 (1975)
64. Mittoo S, "Pulmonary manifestations of systemic lupus erythematosus", Semin Respir Crit Care Med, 35, pp.249~254 (2014)
65. Weinrib L, "A long-term study of interstitial lung disease in systemic lupus erythematosus", Semin Arthritis Rheum, 20, pp.48~56 (1990)
66. Spagnolo P, "Connective tissue diseases, multimorbidity and the ageing lung", Eur Respir J, 47, pp.1535~1558 (2016)
67. Khanna D, "Connective tissue disease-associated interstitial lung diseases (CTD-ILD):report from OMERACT CTD-ILD working group", J Rheumatol, 42, pp.2168~2171 (2015)
68. Goh NS, "Interstitial lung disease in systemic sclerosis: a simple staging system", Am J Respir Crit Care Med, 177, pp.1248~1254 (2008)
69. Roth MD, "Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease", Arthritis Rheum, 63, pp.2797~2808 (2011)
70. Kurita T, "The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis", dermatomyositis, 2015, pp.24, 3~9
71. Khanna D, "A one-year, phase I", IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease, 2011, pp.63, 3540~3546
72. Spiera RF, "Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial", Ann Rheum Dis, 70, pp.1003~1009 (2011)
73. Horai Y, "Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease", J Clin Pharm Ther, 37, pp.117~121 (2012)
74. Perez-Alvarez R, "Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases", Semin Arthritis Rheum, 41, pp.256~264 (2011)
75. 구본산, "Mortality in patients with rheumatoid arthritisassociated interstitial lung disease treated with an anti-tumor necrosis factor agent", The Korean Journal of Internal Medicine, 30(1), pp.104~109 (2015), 대한내과학회[DOI]
76. Mera-Varela A, "Abatacept therapy in rheumatoid arthritis with interstitial lung disease", J Clin Rheumatol, 20, pp.445~446 (2014)
77. Mohr M, "Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade", Scand J Rheumatol, 40, pp.400~401 (2011)
78. Miura Y, "Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease", Sarcoidosis Vasc Diffuse Lung Dis, 31, pp.235~238 (2014)
79. Mauhin W, "Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis", Scand J Rheumatol, 43, pp.170~171 (2014)
80. van Laar JM, "Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis:a randomized clinical trial", JAMA, 311, pp.2490~2498 (2014)
81. Cappelli S, "Interstitial lung disease in systemic sclerosis: where do we stand?", Eur Respir Rev, 24, pp.411~419 (2015)
82. Solomon JJ, "Current approach to connective tissue disease-associated interstitial lung disease", Curr Opin Pulm Med, 20, pp.449~456 (2014)
83. Christie JD, "The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012", J Heart Lung Transplant, 31, pp.1073~1086 (2012)
84. Bernstein EJ, "Survival of adults with systemic sclerosis following lung transplantation:a nationwide cohort study", Arthritis Rheumatol, 67, pp.1314~1322 (2015)
85. Fischer A, "Interstitial lung disease in connective tissue disorders", Lancet, 380, pp.689~698 (2012)
86. Raghu G, "An official ATS", ERS, ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline, pp.Am J Respir Crit Care Med, 2015[DOI]
87. Fischer A, "Cross-disciplinary collaboration in connective tissue disease-related lung disease", Semin Respir Crit Care Med, 35, pp.159~165 (2014)

관련 논문AI추천